|
 |
|
|||||||
|
|||||||||
Correspondence to:
Robert W. Mahley
Type III hyperlipoproteinemia (HLP) is a genetic disorder characterized by accumulation of remnant lipoproteins in the plasma and development of premature atherosclerosis. Although receptor binding-defective forms of apolipoprotein (apo) E are the common denominator in this disorder, a number of apparent paradoxes concerning its pathogenesis still exist. However, studies in transgenic animals are resolving the mechanisms underlying this disorder. Paradox I: Defective apoE (commonly apoE2) is essential but not sufficient to cause overt type III HLP. In fact, most apoE2 homozygotes are hypolipidemic. Studies in apoE2 transgenic models have demonstrated the impact of other genes or hormones in converting the hypolipidemia to hyperlipidemia. Paradox II: Among apoE2 homozygotes, men are more susceptible than women to type III HLP. Transgenic studies have shown that estrogen affects both LDL receptor expression and lipolytic processing, explaining the resistance of women to this disorder until after menopause. Paradox III: ApoE deficiency is associated with hypercholesterolemia, whereas the type III HLP phenotype is characterized by both hypercholesterolemia and hypertriglyceridemia. The hypercholesterolemia is caused by impaired receptor-mediated clearance, whereas the hypertriglyceridemia is caused primarily by impaired lipolytic processing of remnants and increased VLDL production associated with increased levels of apoE. Paradox IV: ApoE2 is associated with recessive inheritance of this disorder, whereas other defective apoE variants are associated with dominant inheritance. Determinants of the mode of inheritance are the differential binding of apoE variants to the LDL receptor versus the HSPG/LRP complex and the preference of certain apoE variants for specific lipoproteins. Thus, the pathogenesis of this sometimes mysterious disorder has been clarified.—Mahley, R. W., Y. Huang, and S. C. Rall, Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J. Lipid Res. 1999. 40: 1933;–1949.
Supplementary key words:
apolipoprotein E, lipoprotein metabolism, heparan sulfate proteoglycans, LDL receptor, lipolysis, ß-VLDL, VLDL production, hypercholesterolemia, hypertriglyceridemia, remnant lipoproteins
Copyright © 1999 by Lipid Research, Inc.
Review
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes
Robert W. Mahleya,b,c,
Yadong Huanga,b, and
Stanley C. Rall, Jr.a
a Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, CA 94141-9100
b Cardiovascular Research Institute, University of California, San Francisco, CA 94141-9100
c Departments of Medicine and Pathology, University of California, San Francisco, CA 94141-9100
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Basaran Pregnancy-induced Hyperlipoproteinemia: Review of the Literature Reproductive Sciences, May 1, 2009; 16(5): 431 - 437. [Abstract] [PDF]
|
|
|
|
 |
|
 R. W. Mahley, K. H. Weisgraber, and Y. Huang Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS J. Lipid Res., April 1, 2009; 50(Supplement): S183 - S188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wu, H. Yang, Y. Zhao, C. Sharan, J. S. Goodwin, L. Zhou, Y. Guo, and Z. Guo 2-Aminopurine Inhibits Lipid Accumulation Induced by Apolipoprotein E-Deficient Lipoprotein in Macrophages: Potential Role of Eukaryotic Initiation Factor-2{alpha} Phosphorylation in Foam Cell Formation J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 395 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fan, S. Qiu, C. D. Overton, P. G. Yancey, L. L. Swift, W. G. Jerome, M. F. Linton, and S. Fazio Impaired Secretion of Apolipoprotein E2 from Macrophages J. Biol. Chem., May 4, 2007; 282(18): 13746 - 13753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Mullick, A. F. Powers, R. S. Kota, S. D. Tetali, J. P. Eiserich, and J. C. Rutledge Apolipoprotein E3- and Nitric Oxide-Dependent Modulation of Endothelial Cell Inflammatory Responses Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 339 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Mahley, K. H. Weisgraber, and Y. Huang Inaugural Article: Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease PNAS, April 11, 2006; 103(15): 5644 - 5651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Heeren, U. Beisiegel, and T. Grewal Apolipoprotein E Recycling: Implications for Dyslipidemia and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 442 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ruiz, D. Kouiavskaia, M. Migliorini, S. Robinson, E. L. Saenko, N. Gorlatova, D. Li, D. Lawrence, B. T. Hyman, K. H. Weisgraber, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor J. Lipid Res., August 1, 2005; 46(8): 1721 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Maheux Dermatology spot diagnosis Postgrad. Med. J., August 1, 2005; 81(958): 497 - 497. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Blom, F. H. O'Neill, and A. D. Marais Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations Clin. Chem., May 1, 2005; 51(5): 904 - 907. [Full Text] [PDF]
|
|
|
|
|
|
M. Futamura, P. Dhanasekaran, T. Handa, M. C. Phillips, S. Lund-Katz, and H. Saito Two-step Mechanism of Binding of Apolipoprotein E to Heparin: IMPLICATIONS FOR THE KINETICS OF APOLIPOPROTEIN E-HEPARAN SULFATE PROTEOGLYCAN COMPLEX FORMATION ON CELL SURFACES J. Biol. Chem., February 18, 2005; 280(7): 5414 - 5422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Marz, H. Scharnagl, M. M. Hoffmann, B. O. Boehm, and B. R. Winkelmann The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study) Eur. Heart J., December 1, 2004; 25(23): 2109 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Janis, S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M.-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample J. Lipid Res., December 1, 2004; 45(12): 2303 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Mann, F. E. Thorngate, Y. Katoh-Fukui, H. Hamanaka, D. L. Williams, S. Fujita, and B. T. Lamb Independent effects of APOE on cholesterol metabolism and brain A{beta} levels in an Alzheimer disease mouse model Hum. Mol. Genet., September 1, 2004; 13(17): 1959 - 1968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ikewaki, W. Cain, F. Thomas, R. Shamburek, L. A. Zech, D. Usher, H. B. Brewer Jr., and D. J. Rader Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency J. Lipid Res., July 1, 2004; 45(7): 1302 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Krimbou, M. Denis, B. Haidar, M. Carrier, M. Marcil, and J. Genest Jr. Molecular interactions between apoE and ABCA1: impact on apoE lipidation J. Lipid Res., May 1, 2004; 45(5): 839 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.B. Twickler, G.M. Dallinga-Thie, J.S. Cohn, and M.J. Chapman Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype Circulation, April 27, 2004; 109(16): 1918 - 1925. [Full Text] [PDF]
|
|
|
|
|
|
H. Saito, P. Dhanasekaran, F. Baldwin, K. H. Weisgraber, M. C. Phillips, and S. Lund-Katz Effects of Polymorphism on the Lipid Interaction of Human Apolipoprotein E J. Biol. Chem., October 17, 2003; 278(42): 40723 - 40729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. DeKroon, M. Mihovilovic, Z. V. Goodger, J. B. Robinette, P. M. Sullivan, A. M. Saunders, and W. J. Strittmatter ApoE genotype-specific inhibition of apoptosis J. Lipid Res., August 1, 2003; 44(8): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hidaka, M. Tozuka, B. Meyer, K. Yamauchi, M. Sugano, T. Nakabayashi, and T. Katsuyama Characterization of Triglyceride Rich Lipoproteins with Very Light Density by Ultracentrifugation and Agarose Gel Electrophoresis using Triglyceride- and Cholesterol-Staining Ann. Clin. Lab. Sci., April 1, 2003; 33(2): 167 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hara, T. Matsushima, H. Satoh, N. Iso-o, H. Noto, M. Togo, S. Kimura, Y. Hashimoto, and K. Tsukamoto Isoform-Dependent Cholesterol Efflux From Macrophages by Apolipoprotein E Is Modulated by Cell Surface Proteoglycans Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 269 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Blom, P. Byrnes, S. Jones, and A. D. Marais Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia J. Lipid Res., January 1, 2003; 44(1): 212 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Ginsberg New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism Circulation, October 15, 2002; 106(16): 2137 - 2142. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hinsdale, P. M. Sullivan, H. Mezdour, and N. Maeda ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice J. Lipid Res., September 1, 2002; 43(9): 1520 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Usui, Y. Hara, S. Hosaki, and M. Okazaki A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC J. Lipid Res., May 1, 2002; 43(5): 805 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Jialal and S. Devaraj Remnant Lipoproteins: Measurement and Clinical Significance Clin. Chem., February 1, 2002; 48(2): 217 - 219. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bernstein, M. C. Costanza, R. W. James, M. A. Morris, F. Cambien, S. Raoux, and A. Morabia Physical Activity May Modulate Effects of ApoE Genotype on Lipid Profile Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 133 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Libeu, S. Lund-Katz, M. C. Phillips, S. Wehrli, M. J. Hernaiz, I. Capila, R. J. Linhardt, R. L. Raffai, Y. M. Newhouse, F. Zhou, et al. New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E J. Biol. Chem., October 12, 2001; 276(42): 39138 - 39144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lund-Katz, S. Wehrli, M. Zaiou, Y. Newhouse, K. H. Weisgraber, and M. C. Phillips Effects of polymorphism on the microenvironment of the LDL receptor-binding region of human apoE J. Lipid Res., June 1, 2001; 42(6): 894 - 901. [Abstract] [Full Text]
|
|
|
|
|
|
R. H. Eckel Familial Combined Hyperlipidemia and Insulin Resistance : Distant Relatives Linked by Intra-abdominal Fat? Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 469 - 470. [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. HOFFMANN, H. SCHARNAGL, E. PANAGIOTOU, W. T. BANGHARD, H. WIELAND, and W. MÄRZ Diminished LDL Receptor and High Heparin Binding of Apolipoprotein E2 Sendai Associated with Lipoprotein Glomerulopathy J. Am. Soc. Nephrol., March 1, 2001; 12(3): 524 - 530. [Abstract] [Full Text]
|
|
|
|
|
|
K. J. Hockey, R. A. Anderson, V. R. Cook, R. R. Hantgan, and R. B. Weinberg Effect of the apolipoprotein A-IV Q360H polymorphism on postprandial plasma triglyceride clearance J. Lipid Res., February 1, 2001; 42(2): 211 - 217. [Abstract] [Full Text]
|
|
|
|
|
|
F. K. Welty, A. H. Lichtenstein, P. H. R. Barrett, J. L. Jenner, G. G. Dolnikowski, and E. J. Schaefer Effects of ApoE Genotype on ApoB-48 and ApoB-100 Kinetics With Stable Isotopes in Humans Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1807 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Tagalakis, I. R. Graham, D. R. Riddell, J. G. Dickson, and J. S. Owen Gene Correction of the Apolipoprotein (Apo) E2 Phenotype to Wild-type ApoE3 by in Situ Chimeraplasty J. Biol. Chem., April 13, 2001; 276(16): 13226 - 13230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Knouff, S. Malloy, J. Wilder, M. K. Altenburg, and N. Maeda Doubling Expression of the Low Density Lipoprotein Receptor by Truncation of the 3'-Untranslated Region Sequence Ameliorates Type III Hyperlipoproteinemia in Mice Expressing the Human ApoE2 Isoform J. Biol. Chem., February 2, 2001; 276(6): 3856 - 3862. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |